Literature DB >> 20619530

Changes in renal function following nephroureterectomy may affect the use of perioperative chemotherapy.

Matthew G Kaag1, Rebecca L O'Malley, Padraic O'Malley, Guilherme Godoy, Mang Chen, Marc C Smaldone, Ronald L Hrebinko, Jay D Raman, Bernard Bochner, Guido Dalbagni, Michael D Stifelman, Samir S Taneja, William C Huang.   

Abstract

BACKGROUND: Nephroureterectomy alone fails to adequately treat many patients with advanced upper tract urothelial carcinoma (UTUC). Perioperative platinum-based chemotherapy has been proposed but requires adequate renal function.
OBJECTIVE: Our aim was to determine whether the ability to deliver platinum-based chemotherapy following nephroureterectomy is affected by postoperative changes in renal function. DESIGN, SETTINGS, AND PARTICIPANTS: We retrospectively reviewed data on 388 patients undergoing nephroureterectomy for UTUC between 1991 and 2009. Four institutions were included. INTERVENTION: All patients underwent nephroureterectomy. MEASUREMENTS: All patients had serum creatinine measured before and after surgery. The value closest to 3 mo after surgery was taken as the postoperative value (range: 2-52 wk). Estimated glomerular filtration rate (eGFR) was calculated using the abbreviated Modification of Diet in Renal Disease study equation. eGFR values before and after surgery were compared using the paired t test. We chose an eGFR of 45 and 60 ml/min per 1.73 m(2) as possible cut-offs for chemotherapy eligibility and compared eligibility before and after surgery using the chi-square test. RESULTS AND LIMITATIONS: Our cohort of 388 patients included 233 men (60%) with a median age of 70 yr. Mean eGFR decreased by 24% after surgery. Using a cut-off of 60 ml/min per 1.73 m(2), 49% of patients were eligible for chemotherapy before surgery, but only 19% of patients remained eligible postoperatively. Using a cut-off of 45 ml/min per 1.73 m(2), 80% of patients were eligible preoperatively, but only 55% remained eligible after surgery. This distribution persisted when we limited the analysis to patients with advanced pathologic stage (T3 or higher). Patients older than the median age of 70 yr were more likely to be ineligible for chemotherapy both pre- and postoperatively by either definition, and they were significantly more likely to have an eGFR <45 ml/min per 1.73 m(2) postoperatively, regardless of their starting eGFR. This study is limited by its retrospective nature, and there was some variability in the timing of postoperative serum creatinine measurements.
CONCLUSIONS: eGFR is significantly diminished after nephroureterectomy, particularly in elderly patients. These changes in renal function likely affect eligibility for adjuvant cisplatin-based therapy. Accordingly, we suggest strong consideration of neoadjuvant regimens. Copyright 2010 European Association of Urology. Published by Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20619530      PMCID: PMC3677959          DOI: 10.1016/j.eururo.2010.06.029

Source DB:  PubMed          Journal:  Eur Urol        ISSN: 0302-2838            Impact factor:   20.096


  27 in total

1.  Upper tract urothelial neoplasms: incidence and survival during the last 2 decades.

Authors:  J J Munoz; L M Ellison
Journal:  J Urol       Date:  2000-11       Impact factor: 7.450

2.  Estimation of the glomerular filtration rate in cancer patients: a new formula for new drugs.

Authors:  Patrick T Murray; Mark J Ratain
Journal:  J Clin Oncol       Date:  2003-07-15       Impact factor: 44.544

Review 3.  Overview of bladder cancer trials in the European Organization for Research and Treatment.

Authors:  Ronald de Wit
Journal:  Cancer       Date:  2003-04-15       Impact factor: 6.860

4.  Gemcitabine and carboplatin in advanced transitional cell carcinoma of the urinary tract: an alternative therapy.

Authors:  Miquel Nogué-Aliguer; Joan Carles; Antonio Arrivi; Oscar Juan; Lorenzo Alonso; Albert Font; Begoña Mellado; Pilar Garrido; Alberto Sáenz
Journal:  Cancer       Date:  2003-05-01       Impact factor: 6.860

5.  Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction.

Authors:  Nagesh S Anavekar; John J V McMurray; Eric J Velazquez; Scott D Solomon; Lars Kober; Jean-Lucien Rouleau; Harvey D White; Rolf Nordlander; Aldo Maggioni; Kenneth Dickstein; Steven Zelenkofske; Jeffrey D Leimberger; Robert M Califf; Marc A Pfeffer
Journal:  N Engl J Med       Date:  2004-09-23       Impact factor: 91.245

6.  Adjuvant chemotherapy for high risk upper tract urothelial carcinoma: results from the Upper Tract Urothelial Carcinoma Collaboration.

Authors:  Nicholas J Hellenthal; Shahrokh F Shariat; Vitaly Margulis; Pierre I Karakiewicz; Marco Roscigno; Christian Bolenz; Mesut Remzi; Alon Weizer; Richard Zigeuner; Karim Bensalah; Casey K Ng; Jay D Raman; Eiji Kikuchi; Francesco Montorsi; Mototsugu Oya; Christopher G Wood; Mario Fernandez; Christopher P Evans; Theresa M Koppie
Journal:  J Urol       Date:  2009-07-17       Impact factor: 7.450

7.  Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer.

Authors:  H Barton Grossman; Ronald B Natale; Catherine M Tangen; V O Speights; Nicholas J Vogelzang; Donald L Trump; Ralph W deVere White; Michael F Sarosdy; David P Wood; Derek Raghavan; E David Crawford
Journal:  N Engl J Med       Date:  2003-08-28       Impact factor: 91.245

8.  Cancer statistics, 2009.

Authors:  Ahmedin Jemal; Rebecca Siegel; Elizabeth Ward; Yongping Hao; Jiaquan Xu; Michael J Thun
Journal:  CA Cancer J Clin       Date:  2009-05-27       Impact factor: 508.702

9.  Adjuvant chemotherapy with paclitaxel and carboplatin in patients with advanced carcinoma of the upper urinary tract: a study by the Hellenic Cooperative Oncology Group.

Authors:  A Bamias; Ch Deliveliotis; G Fountzilas; D Gika; A Anagnostopoulos; M P Zorzou; E Kastritis; C Constantinides; P Kosmidis; M A Dimopoulos
Journal:  J Clin Oncol       Date:  2004-06-01       Impact factor: 44.544

10.  A phase I/II study of gemcitabine and fractionated cisplatin in an outpatient setting using a 21-day schedule in patients with advanced and metastatic bladder cancer.

Authors:  S A Hussain; D D Stocken; P Riley; D H Palmer; D R Peake; J I Geh; D Spooner; N D James
Journal:  Br J Cancer       Date:  2004-08-31       Impact factor: 7.640

View more
  58 in total

1.  Combining imaging and ureteroscopy variables in a preoperative multivariable model for prediction of muscle-invasive and non-organ confined disease in patients with upper tract urothelial carcinoma.

Authors:  Ricardo L Favaretto; Shahrokh F Shariat; Caroline Savage; Guilherme Godoy; Daher C Chade; Matthew Kaag; Bernard H Bochner; Jonathan Coleman; Guido Dalbagni
Journal:  BJU Int       Date:  2011-06-01       Impact factor: 5.588

Review 2.  [Upper tract urothelial carcinoma. An update on clinical and pathological prognostic factors].

Authors:  M Rink; M Adam; J Hansen; F K Chun; S A Ahyai; M Remzi; T Schlomm; O Engel; R Heuer; C Eichelberg; M Fisch; R Dahlem; S F Shariat
Journal:  Urologe A       Date:  2012-09       Impact factor: 0.639

3.  Prognostic importance of lymphovascular invasion in urothelial carcinoma of the renal pelvis.

Authors:  Matthew R Danzig; Katherine Mallin; James M McKiernan; Walter M Stadler; Srikala S Sridhar; Todd M Morgan; Bernard H Bochner; Cheryl T Lee
Journal:  Cancer       Date:  2018-04-06       Impact factor: 6.860

Review 4.  [Application of totally extraperitoneal renal autotransplantation with Boari flap-pelvis anastomosis in upper urinary tract urothelial carcinomas treatment].

Authors:  S D Cheng; W Q Li; L Mu; G P Ding; B Zhang; C Shen; Z W Ying; K L Yang; H Hao; X S Li; L Q Zhou
Journal:  Beijing Da Xue Xue Bao Yi Xue Ban       Date:  2019-08-18

5.  Oncological and renal outcomes of segmental ureterectomy vs. radical nephroureterectomy for upper tract urothelial carcinoma.

Authors:  Tomonori Kato; Ryo Nakayama; Tomomi Haba; Makoto Kawaguchi; Akira Komiya; Hiroshi Koike
Journal:  Oncol Lett       Date:  2018-09-19       Impact factor: 2.967

6.  Sequential chemotherapy using gemcitabine + carboplatin followed by gemcitabine + carboplatin + docetaxel for advanced upper-tract urothelial cancer.

Authors:  Takahiro Yoneyama; Atsushi Imai; Shingo Hatakeyama; Yasuhiro Hashimoto; Takuya Koie; Chikara Ohyama
Journal:  Int J Clin Oncol       Date:  2015-05-26       Impact factor: 3.402

7.  Upper urinary tract urothelial carcinoma: what have we learned in the last 4 years?

Authors:  Mesut Remzi; Shahrokh Shariat; Wilhelm Huebner; Harun Fajkovic; Christian Seitz
Journal:  Ther Adv Urol       Date:  2011-04

Review 8.  Perioperative chemotherapy in upper tract urothelial carcinoma: a comprehensive review.

Authors:  Atiqullah Aziz; Jakub Dobruch; Kees Hendricksen; Luis A Kluth; Andrea Necchi; Aidan Noon; Michael Rink; Florian Roghmann; Roland Seiler; Paolo Gontero; Wassim Kassouf; Shahrokh F Shariat; Evanguelos Xylinas
Journal:  World J Urol       Date:  2017-01-10       Impact factor: 4.226

9.  Neoadjuvant chemotherapy improves survival of patients with upper tract urothelial carcinoma.

Authors:  Sima Porten; Arlene O Siefker-Radtke; Lianchun Xiao; Vitaly Margulis; Ashish M Kamat; Christopher G Wood; Eric Jonasch; Colin P N Dinney; Surena F Matin
Journal:  Cancer       Date:  2014-03-13       Impact factor: 6.860

10.  Current status of systemic chemotherapy for octogenarians with advanced urothelial cancer in Japan: a Japanese multi-institutional study (CURE study).

Authors:  Yoshiyuki Matsui; Osamu Ogawa; Ryutaro Ishitsuka; Jun Miyazaki; Takamitsu Inoue; Susumu Kageyama; Mikio Sugimoto; Koji Mitsuzuka; Yusuke Shiraishi; Hidefumi Kinoshita; Hironobu Wakeda; Takeshi Nomoto; Eiji Kikuchi; Keiko Fujie; Naoto Keino; Hiroyuki Nishiyama
Journal:  Int J Clin Oncol       Date:  2016-06-27       Impact factor: 3.402

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.